Citations

Showing 10 of 108083 citations.

IDENTIFICATION AND INVESTIGATION OF SENESCENT CELLS IN SKELETAL MUSCLE AGING
Habiballa, Leena , Aversa, Zaira, Ng, Yan Er, Zhang, Xu , Ng, Yan Er , Passos, João F. , LeBrasseur, Nathan K.

Mayo Clinic

Innovation in Aging | December 20, 2022 | Volume: 6 | Issue: Supplement_1 | Pages: 196-196

10.1093/geroni/igac059.785 Get It

Abstract Skeletal muscle aging is marked by the loss and atrophy of resident fibers, and the accumulation of functionally diverse cell types including fibroblasts, adipocytes, and immune cells. Senescent cells amass in multiple tissues with advancing age where they contribute to aging, chronic disease, and physical decline. The role of senescence in mediating muscle aging has become a popular and sometimes contentious topic. However, to date, this concept has not been methodically tested. In this study, we characterized the changes in cell abundance and, importantly, cell-specific transcriptional profiles with skeletal muscle aging using scRNAseq. Interestingly, we identified a small population of p16 positive fibro-adipogenic progenitors (FAPs) which, upon further investigation using immunohistochemical methods, were found to express other senescence markers. This subpopulation of FAPs did not exhibit elevation in p21 levels with age. Instead, terminally differentiated myofibers were the source of the p21 increase. Myofibers with high p21 expression exhibit a strong inflammatory phenotype, which includes activated p53 signaling pathways together with strong cytokine-cytokine receptor interactions. We further identified large amounts of cross-talk between different cell types, suggesting that senescent FAPs and myofibers could contribute to skeletal muscle aging in a paracrine manner. Importantly, these observations in mice were confirmed in human samples, suggesting the strong translational power of these findings.
ASSOCIATIONS OF AUDIOMETRIC HEARING, BRAIN MRI, AND COGNITIVE PERFORMANCE WITH SPEECH-IN-NOISE PERFORMANCE
Mosley, Thomas, Lin, Frank R. , Jiang, Kening , Coresh, Josef , Hayden, Kathleen M. , Jack, Clifford R. , Mosley, Thomas, Pankow, James S. , Deal, Jennifer A.

Mayo Clinic

Innovation in Aging | December 20, 2022 | Volume: 6 | Issue: Supplement_1 | Pages: 152-152

10.1093/geroni/igac059.606 Get It

Abstract Speech-in-noise performance is fundamental to daily communications and comprehensive characterization is needed. We studied 590 dementia-free participants aged 70-84 years, including 428 hearing-impaired participants from the Aging and Cognitive Health Evaluation in Elders (ACHIEVE) study baseline (2018-19), which is a randomized controlled trial partially nested within the Atherosclerosis Risk in Communities (ARIC) Study, and 162 normal-hearing ARIC Visit 6/7 (2016-17/2018-19) participants. The Quick Speech-in-Noise (QuickSIN) test was used to measure speech-in-noise performance. Predictors included (1) Four-frequency better-ear pure-tone average (PTA); (2) Magnetic resonance imaging (MRI) measures (total and lobar volumes, diffusion tensor imaging, white matter hyperintensities); (3) Global and domain-specific (language, memory, executive function) cognitive performance. All predictors were standardized to Z-scores. We used multivariable-adjusted linear regression, adjusting for demographic and disease covariates. PTA and cognitive performance, but not MRI measures, were independently associated with speech-in-noise performance, with PTA explaining the largest variance, indicating the promising role of hearing aids.
Artificial intelligence–augmented electrocardiography for left ventricular systolic dysfunction in patients undergoing high-sensitivity cardiac troponin T
Knott, Jonathan D , Attia, Zachi I. , Ola, Olatunde , Mehta, Ramila A. , Akula, Ashok , Hodge, David O. , Gulati, Rajiv , Friedman, Paul A. , Jaffe, Allan S. , Sandoval, Yader , Attia, Zachi I , Friedman, Paul A , Sandoval, Yader , Michieli, Laura De , Jaffe, Allan S.

Mayo Clinic

European Heart Journal. Acute Cardiovascular Care | December 20, 2022 | Volume: 12 | Issue: 2 | Pages: 106-114

10.1093/ehjacc/zuac156 | PMID 36537652 Get It

Abstract Aims Our goal was to evaluate a previously validated artificial intelligence–augmented electrocardiography (AI-ECG) screening tool for left ventricular systolic dysfunction (LVSD) in patients undergoing high-sensitivity-cardiac troponin T (hs-cTnT). Methods and results Retrospective application of AI-ECG for LVSD in emergency department (ED) patients undergoing hs-cTnT. AI-ECG scores (0–1) for probability of LVSD (left ventricular ejection fraction ≤ 35%) were obtained. An AI-ECG score ≥0.256 indicates a positive screen. The primary endpoint was a composite of post-discharge major adverse cardiovascular events (MACEs) at two years follow-up. Among 1977 patients, 248 (13%) had a positive AI-ECG. When compared with patients with a negative AI-ECG, those with a positive AI-ECG had a higher risk for MACE [48 vs. 21%, P < 0.0001, adjusted hazard ratio (HR) 1.39, 95% confidence interval (CI) 1.11–1.75]. This was largely because of a higher rate of deaths (32 vs. 14%, P < 0.0001; adjusted HR 1.26, 95% 0.95–1.66) and heart failure hospitalizations (26 vs. 6.1%, P < 0.001; adjusted HR 1.75, 95% CI 1.25–2.45). Together, hs-cTnT and AI-ECG resulted in the following MACE rates and adjusted HRs: hs-cTnT < 99th percentile and negative AI-ECG: 116/1176 (11%; reference), hs-cTnT < 99th percentile and positive AI-ECG: 28/107 (26%; adjusted HR 1.54, 95% CI 1.01–2.36), hs-cTnT > 99th percentile and negative AI-ECG: 233/553 (42%; adjusted HR 2.12, 95% CI 1.66, 2.70), and hs-cTnT > 99th percentile and positive AI-ECG: 91/141 (65%; adjusted HR 2.83, 95% CI 2.06, 3.87). Conclusion Among ED patients evaluated with hs-cTnT, a positive AI-ECG for LVSD identifies patients at high risk for MACE. The conjoint use of hs-cTnT and AI-ECG facilitates risk stratification.
Mood and Anxiety Disorders and Suicidality in Patients With Newly Diagnosed Focal Epilepsy
Saporta, A. , Barry, John J., Omotola, Hope, O’Brien, Terence J. , Nadkarni, Siddhartha, Winawer, Melodie R., French, Jacqueline A. , Abou‐Khalil, Bassel , Alldredge, Brian K., Bebin, Martina , Cascino, Gregory D. , Cook, Mark , Detyniecki, Kamil , Dlugos, Dennis , Faught, Edward, Ficker, David M. , Fields, Madeline , Glynn, Simon, Halford, Jonathan J. , Haut, Sheryl R., Hegde, Manu , Kälviäinen, Reetta , Knowlton, Robert C. , Krishnamurthy, Kaarkuzhali Babu , Kwan, Patrick , Lowenstein, Daniel H. , Marcuse, Lara , Meador, Kimford J. , Mintzer, Scott , Pardoe, Heath , Penovich, Patricia , Singh, Rani K. , Szabó, C. Ákos , Szaflarski, Jerzy P. , Burneo, Jorge G. , Project, and the Human Epilepsy, French, Jacqueline A. , Kanner, Andres M, Saporta, Anita S, Kim, Dong H, Altalib, Hamada , Jetté, Nathalie , O'Brien, Terence J, Sperling, Michael, Abou-Khalil, Bassel, Alldredge, Brian, Cook, Mark J , Ficker, David, Gidal, Barry, Gelfand, Michael , Haut, Sheryl, Holmes, Manisha G, Kang, Joon, Klein, Pavel , Krishnamurthy, Kaarkuzhali, Kuzniecky, Ruben , Pardoe, Heath R , Park, Kristen , Szabo, Charles A, Lin Thio, K Liu, Halford, Jonathan J , French, Jacqueline , Meador, Kimford J , Burneo, Jorge G , Kanner, Andres Miguel , Kim, Dong , Sperling, Michael R. , Cole, Andrew J. , Devinsky, Orrin , Gidal, Barry E. , Holmes, Manisha , Kang, Joon Won , Somerville, Ernest , Thio, Liu Lin , Trinka, Eugen , Project, and the Human Epilepsy

Mayo Clinic

Neurology | December 20, 2022 | Volume: 100 | Issue: 11 | Pages: No page available

10.1212/wnl.0000000000201671 | PMID 36539302 Get It

Injectable bioactive copper-based metal organic framework embedded dual-crosslinked alginate hydrogel for potential antimicrobial applications
Gwon, Kihak , Lee, Seonhwa , Choi, Jun , Kim, Sujin , Kim, Sung‐Jin , Hwang, Youngmin , Lee, Do Nam , Gwon, Kihak , Kim, Youngmee , Hong, Hye Jin , Mori, Munemasa

Mayo Clinic

No container title available | December 20, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2352401/v1 Get It

Abstract Background: The antibiotic resistance of pathogenic microbes due to the overuse of antibiotics is a growing threat to the public health and can eventually reduce the therapeutic effects of antibiotics. Hydrogel-based systems for local delivery of antibiotics can be a solution to this problem. Metal-organic frameworks (MOFs) have received considerable interest for use as antimicrobial materials due to their high porosity, large surface area to volume, diverse structures, and tunable topologies. Methods: In this study, we developed MOF-encapsulated and dual (photo & chemical)-crosslinkable alginate hydrogel as an antimicrobial scaffold. We synthesized antimicrobial Cu(AZPY)-MOF using solvothermal reaction and encapsulated them in an alginate-based hydrogel via visible light photo-crosslinking and calcium ion-induced chemical-crosslinking processes. Results: Powder X-ray diffraction, Fourier-transform infrared spectroscopy, thermogravimetric analysis, and scanning electron microscopy confirmed the successful fabrication of Cu(AZPY)-MOF encapsulated alginate hydrogel. The mechanical strength of the dual-crosslinked hydrogels was better than that of the photo-crosslinked hydrogel. Encapsulation of Cu(AZPY)-MOF in an alginate hydrogel resulted in a further increase in the mechanical strength of the hydrogel owing to the additional interaction of alginate with Cu-MOF. Moreover, the Cu(AZPY)-MOF encapsulated alginate hydrogel exhibited excellent antibacterial and antifungal properties against two bacterial strains (i.e., MRSA and S. mutans) and one fungal strain (C. albicans) as well as negligible cytotoxicity toward MEFs. Conclusions: The antimicrobial agents encapsulated dual-crosslinkable alginate hydrogel developed in this study is a promising candidate for use in tissue engineering and biomedical field.
In a Hurry Not to Rush
Valle, Kathryn T. del , Del Valle, Kathryn T, Del Valle, Kathryn T

Mayo Clinic

Academic Medicine | December 20, 2022 | Volume: 98 | Issue: 6 | Pages: 653-654

10.1097/acm.0000000000005060 | PMID 36538688 Get It

“The Practice of My Art”: Finding Synergy in Creative and Clinical Pursuits
Lee, Yeonsoo Sara , Bihun, Rebekah J. , Bihun, Rebekah , Sara Lee, Yeonsoo

Mayo Clinic

Academic Medicine | December 20, 2022 | Volume: 98 | Issue: 7 | Pages: 763-763

10.1097/acm.0000000000005062 | PMID 36538692 Get It

Outcomes of concomitant aortic valve procedures and left ventricular assist device implantation: A systematic review and meta‐analysis
Iqbal, Kinza , Kumar, Pankaj , Iqbal, Ayman , Arif, Taha Bin , Rathore, Sawai Singh , Ahmed, Jawad , Shahid, Izza , Shariff, Mariam , Kumar, Ashish

Mayo Clinic

Artificial Organs | December 20, 2022 | Volume: 47 | Issue: 3 | Pages: 470-480

10.1111/aor.14482 | PMID 36537993 Get It

AbstractBackgroundLeft ventricular assist device (LVAD) implantation is frequently employed in patients with end‐stage heart failure. The outcomes of addressing the repair of all substantial aortic valvular disease at the time of LVAD implantation remain unclear. We sought to assess the clinical outcomes in patients undergoing LVAD implantation concomitant with aortic valve procedures (AVPs) compared with isolated LVAD implantation.MethodsA literature search was performed using PubMed, Embase, and Cochrane library from inception till June 2022. Primary outcomes included short‐term mortality and long‐term survival. Random effects models were used to compute mean differences and odds ratios with 95% confidence intervals (CIs).ResultsA total of 14 observational studies (N = 52 693) met our inclusion criteria. Concomitant LVAD implantation and AVPs were associated with higher short‐term mortality (OR = 1.61 [95% CI, 1.06–2.42]; p = 0.02) and mean CPBt (MD = 43.25 [95% CI, 22.95–63.56]; p < 0.0001), and reduced long‐term survival (OR = 0.70 [95% CI, 0.55–0.88]; p = 0.003) compared with isolated LVAD implantation. No difference in the odds of cerebrovascular accident (OR = 1.05 [95% CI, 0.79–1.39]; p = 0.74) and mean length of hospital stay (MD = 2.89 [95% CI, −4.04 to 9.82]; p = 0.41) was observed between the two groups. On adjusted analysis, short‐term mortality was significantly higher in the LVAD group with concurrent AVPs when compared with the isolated LVAD group (aHR = 1.50 [95% CI, 1.20–1.87]; p = 0.0004).ConclusionsConcurrent AVPs were associated with higher short‐term mortality and reduced long‐term survival in patients undergoing LVAD implantation compared with isolated LVAD implantation.
Acute vasoreactivity testing during right heart catheterization in chronic thromboembolic pulmonary hypertension: Results from the pulmonary vascular disease phenomics study
Frantz, Robert P. , Mathai, Stephen C. , Larive, A. Brett, Park, Margaret , Hill, Nicholas S. , Hill, Nicholas S , Frantz, Robert P , Mathai, Stephen C , Leopold, Jane A. , Hassoun, Paul M. , Hemnes, Anna R. , Horn, Evelyn M. , Rischard, Franz , Tang, W.H. Wilson , Rosenzweig, Erika B.

Mayo Clinic

Pulmonary Circulation | December 20, 2022 | Volume: 13 | Issue: 1 | Pages: No page available

10.1002/pul2.12181 | PMID 36618713 Get It

AbstractChronic thromboembolic pulmonary hypertension (CTEPH) is believed to involve both vascular obstruction and vasoconstriction; hence, pulmonary vasodilators such as riociguat may be beneficial. Acute vasoreactivity testing (AVT) is seldom performed routinely in CTEPH patients, so there is limited understanding of the frequency and significance of an acute vasodilator response. Systematic vasodilator testing with oxygen (O2) and oxygen plus inhaled nitric oxide (O2 + iNO) was performed as part of the Pulmonary Vascular Disease Omics (PVDOMICS) NHLBI project, providing an opportunity to examine AVT responses in CTEPH. Patients with CTEPH enrolled in PVDOMICS (n = 49, 40 with prevalent CTEPH [82%]) underwent right heart catheterization including AVT with O2 and O2 + iNO. Hemodynamics were obtained at baseline and with each challenge. Fourteen of 49 patients (29%) had >20% drop in pulmonary vascular resistance (PVR) with O2. With O2 + iNO, 30/49 (61%) had >20% drop in PVR, 20% had >20% drop in mean pulmonary artery pressure (mPAP) and PVR, and 8% had >10 mmHg decline in mPAP to mPAP < 40 with normal cardiac output. Patients on riociguat had less response to O2 + iNO than patients on phosphodiesterase‐5 inhibitors. Our findings shed light on the significant variability in vascular tone that is present in CTEPH, confirming that CTEPH represents a combination of mechanical obstruction and vasoconstriction that appears similar to that observed with Group 1 PAH. Additional study regarding whether results of acute vasodilator testing predict response to therapy and relate to prognosis is warranted.
Plasma levels of an N‐terminal tau fragment predict core AD and neurodegenerative biomarkers in autosomal dominant Alzheimer’s disease: Findings from DIAN
Ostaszewski, Beth L., Fitzpatrick, Colleen , Fagan, Anne M. , Farlow, Martin R. , Schofield, Peter W., Perrin, Richard J. , Johnson, Keith A., Chhatwal, Jasmeer P. , Network, Dominantly Inherited Alzheimer, Schultz, Stephanie A. , Liu, Lei , Xiong, Chengjie , Noble, James M. , Rosa-Neto, Pedro , Schofield, Peter W., Morris, John C. , Jucker, Mathias , Jack, Clifford R. , Karch, Celeste M. , Gordon, Brian A. , Johnson, Keith A. , McDade, Eric , Sperling, Reisa Anne , Bateman, Randall J. , Selkoe, Dennis J. , Network, Dominantly Inherited Alzheimer

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S6 | Pages: No page available

10.1002/alz.069285 Get It

AbstractBackgroundBlood based biomarkers that predict cognitive decline and Alzheimer’s disease (AD) pathology have the potential to accelerate AD therapeutic development and improve clinical care. Prior work suggests that plasma biomarkers of tau pathology (particularly post‐translational modifications of tau) may be highly useful in diagnosis and risk stratification for AD‐related neurodegeneration and cognitive decline. Levels of tau species lacking truncation of the N‐terminal region, particularly plasma and cerebrospinal fluid (CSF) levels of N‐terminal tau fragment 1 (NT1), have previously been shown to predict cognitive decline, neurodegeneration, and tau pathology in preclinical and symptomatic late‐onset AD. Here we examined plasma NT1 as a possible predictor of cognitive, clinical, pathologic, and neurodegenerative trajectories in autosomal dominant AD (ADAD) using data from the Dominantly Inherited Alzheimer Network Observational Study (DIAN‐Obs).MethodsAssociations between plasma NT1 levels and Mini‐Mental State Exam (MMSE), Clinical Dementia Rating SumBox® (CDR‐SB), hippocampal volume (HV), estimated years to symptom onset (EYO), Pittsburgh‐Compound‐B PET, and CSF Aβ42, and p‐tau181 were assessed using linear regression (150 pathogenic variant carriers, 81 non‐carriers; mean[SD] carrier age = 40.1 [10.4] years and EYO = ‐5.4 [10.4]). Plasma NT1 was measured using the Quanterix HD‐X platform. PET, MRI, clinical, and biofluid measures were derived using previously described procedures in DIAN‐Obs.ResultsCross‐sectional plasma NT1 levels in ADAD carriers were significantly associated with MMSE, CDR‐SB, HV, and p‐tau181 even after adjusting for EYO (Table 1; Figure 1). NT1 levels statistically diverged between carriers and non‐carriers 6.8 years before estimated symptom onset (Figure 2). In contrast, plasma NT1 levels were not significantly correlated with measures of β‐amyloid pathology after adjusting for EYO.ConclusionPlasma NT1 levels mirrored changes in clinical, cognitive, and neurodegenerative measures in ADAD, particularly in late asymptomatic and early symptomatic phases of disease. NT1 levels correlated with CSF measures of tau pathology, but NT1 levels were not strongly associated with CSF or PET measures of β‐amyloid pathology, unlike some previously‐studied plasma tau measures. Together with previous supportive findings in preclinical and symptomatic sporadic AD, these results suggest that plasma NT1 may be a useful biomarker of AD‐related tau pathology and neurodegeneration across a broad spectrum of disease.